Recon: FDA approves Mirati’s lung cancer drug; Takeda buys Nimbus psoriasis drug for up to $6B
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy